Rights extend across the EU, UK, Switzerland, Norway and Iceland
August 20, 2026
Global pharma major Lupin Limited (“Lupin”) today announced that VISUfarma B.V. (“VISUfarma”), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with Visus Therapeutics Inc., USA, a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited (“Tenpoint”). This partnership provides VISUfarma the exclusive rights to undertake regulatory activities, commercialization, marketing, promotion, distribution and sale of YUVEZZITM (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, a proprietary ophthalmic product indicated for the treatment of presbyopia in adults, in the European Union, the United Kingdom, Switzerland, Norway and Iceland (Licensed Territories).
Under the agreement, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus, individually or collectively, will also be eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based on net sales.
HEAR FROM THE CEOS
Vinita Gupta, CEO, Lupin, said, “We are delighted to partner with Tenpoint Therapeutics to bring a novel ophthalmic therapy that advances our Specialty Care strategy. Building on the strategic acquisition of VISUfarma, this partnership further strengthens our vision care franchise and expands our presence across key European markets. The addition of YUVEZZITM underscores our commitment to broadening access to differentiated therapies, improving patient outcomes and reinforcing our leadership in eyecare across the Licensed Territories.”
“This exciting partnership marks an important step for Tenpoint as we continue our work to make YUVEZZITM available for the millions of patients with presbyopia and eyecare professionals around the world,” said Henric Bjarke, CEO, Tenpoint. “Lupin’s strong commercial operations span major European markets, and its specialty ophthalmology company VISUfarma’s longstanding presence in eyecare makes them an excellent partner. We look forward to working together as we bring YUVEZZITM to Europe.”
Tenpoint is advancing commercialization of YUVEZZITM in the United States following its recent U.S. FDA approval. This further expands the reach of YUVEZZITM through strategic regional partnerships worldwide, and Tenpoint has already submitted an MMA in the UK, via the MHRA’s International Recognition Procedure. It will continue to execute its plans for regulatory applications for YUVEZZITM in other key regions worldwide.
YUVEZZITM Important Safety Information
Do not use YUVEZZI if you are allergic to any of its ingredients or if you currently have inflammation of the iris (iritis).
Before taking YUVEZZI, tell your doctor if you have depression, low blood pressure, or circulation problems.
YUVEZZI may cause temporary blurry, dim or dark vision. If you experience this, avoid driving, using machinery and participating in hazardous activities. Use caution when night driving and in other activities in low light.
Call your doctor right away if you suddenly have flashes of light, floaters, or vision loss.
Do not let the tip of the vial touch your eye, eyelid, or any other surface.
The most common side effects of YUVEZZI are headache, impaired vision, and temporary eye pain and/or eye irritation upon use. These are not all of the possible side effects of YUVEZZI.
Most side effects were generally mild, didn’t last long, and went away on their own.
